Edition:
India

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.01USD
17 Nov 2017
Change (% chg)

$0.01 (+1.00%)
Prev Close
$1.00
Open
$0.99
Day's High
$1.03
Day's Low
$0.99
Volume
12,467
Avg. Vol
73,293
52-wk High
$1.38
52-wk Low
$0.80

Chart for

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

BRIEF-BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

* BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

18 Oct 2017

BRIEF-BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

* BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration Source text for Eikon: Further company coverage:

26 Sep 2017

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization

21 Aug 2017

BRIEF-Biolinerx Q2 ‍loss per share $0.05​

* Qtrly ‍loss per share $0.05​ Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Biolinerx announces additional investment from BVF Partners L.P.

* BiolineRx announces additional investment from BVF partners L.P.

26 Jul 2017

BVF raises stake in biopharma firm BioLineRx to 24.9 pct

* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.

26 Jul 2017

BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

01 Jun 2017

BRIEF-BioLine Rx reports Q1 loss per share $0.06

* BioLine Rx Ltd qtrly loss per share $0.06 Source text for Eikon: Further company coverage:

25 May 2017

BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040

* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML

22 May 2017

Earnings vs. Estimates